Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6104923 | 1.00 | F10 (0.57) | F10F2USP2MAPTSMN1; SMN2 | |
| SCHEMBL6105426 | 0.97 | F10 (0.58) | F10USP2MAPTSMN1; SMN2 | |
| SCHEMBL6105412 | 0.97 | F10 (0.58) | F10USP2MAPTSMN1; SMN2 | |
| SCHEMBL6103402 | 0.88 | F10 (0.51) | F10 | |
| SCHEMBL6103395 | 0.88 | F10 (0.51) | F10 | |
| SCHEMBL6104355 | 0.88 | F10 (0.45) | F10 | |
| SCHEMBL5433564 | 0.87 | F10 (0.73) | F10F2USP2MAPTSMN1; SMN2 | |
| SCHEMBL5433569 | 0.87 | F10 (0.73) | F10F2USP2MAPTSMN1; SMN2 | |
| SCHEMBL6103464 | 0.86 | F10 (0.78) | F10 | |
| SCHEMBL6103469 | 0.86 | F10 (0.78) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135515-A1 | Heterocyclic amides and their use treating thromboembolic diseases and tumors | MERCK PATENT GMBH (DE) | 2006-06-22 | — | — | US | claimed |
| US-20060135515-A1 | Heterocyclic amides and their use treating thromboembolic diseases and tumors | MERCK PATENT GMBH (DE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135515-A1 | Heterocyclic amides and their use treating thromboembolic diseases and tumors | F2, F11, F12 | F10 4/4885F2 1/4885USP2 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.